Flasar Mark H, Cross Raymond K, Doman David B
Division of Gastroenterology and Hepatology at the University of Maryland School of Medicine, Baltimore, Maryland, USA.
Gastroenterol Hepatol (N Y). 2011 Nov;7(11):720-7.
Ulcerative colitis (UC), a chronic inflammatory bowel disease, occurs in genetically susceptible individuals who mount inappropriate immune responses to endoluminal antigens. Serologic and genetic markers have shown great potential for clinical application in Crohn's disease (CD), particularly for prognostication. However, their use is not as well established in UC. The aim of this paper is to highlight the clinical relevance of these markers for diagnostics and prognostication in UC. This review identified studies that cited the use of serum and genetic biomarkers in UC when these biomarkers were used in diagnostic, prognostic, and therapeutic response prediction applications. Several serologic and genetic markers associated with UC were identified, and this review presents and summarizes these data, focusing on the biomarkers' established and emerging diagnostic and prognostic utility. Although more established in CD, the data provided by serologic and genetic testing in UC has the potential to enhance clinical decision making.
溃疡性结肠炎(UC)是一种慢性炎症性肠病,发生于对肠腔内抗原产生不适当免疫反应的遗传易感个体。血清学和基因标志物在克罗恩病(CD)的临床应用中显示出巨大潜力,尤其是在预后判断方面。然而,它们在UC中的应用尚未得到充分确立。本文旨在强调这些标志物在UC诊断和预后判断中的临床相关性。本综述纳入了在诊断、预后判断和治疗反应预测应用中引用血清和基因生物标志物用于UC的研究。确定了几种与UC相关的血清学和基因标志物,本综述展示并总结了这些数据,重点关注生物标志物已确立的和新出现的诊断及预后效用。尽管血清学和基因检测在CD中应用更为成熟,但在UC中提供的数据仍有可能改善临床决策。